NEW MJ NEWS

AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-host-fourth-quarter-2022-earnings-conference-call-301711231.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Jushi Holdings Inc. (JUSHF) Completes Acquisition of Licensed Cultivator in Ohio

Jushi Holdings Inc. Completes Acquisition of Licensed Cultivator in Ohio Jushi Holdings…

Future Farm Technologies Inc. (FFRMF) Positioned to Launch Significant Expansion of Clínica Verde

Future Farm’s Puerto Rico Affiliate Positioned to Launch Significant Expansion of Clínica…

GrowGeneration Corp. (GRWG) to Participate in Upcoming Virtual Conferences

GrowGeneration Corp. to Participate in Upcoming Virtual Conferences GrowGeneration Corp. (NASDAQ: GRWG),…

Omni Health, Inc., (OMHE) Announced Development of New Drug Candidate

Omni Health Announced Development of New Drug Candidate Omni Health, Inc., (OTC: OMHE),…